Holen Sie sich die Stockscreener-App
1.43
3.38%
-0.05
Handel nachbörslich:
1.48
0.05
+3.50%
Allarity Therapeutics Inc Aktie (ALLR) Neueste Nachrichten
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
ALLR Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineNet Profit Margin - newsline.com
ALLR Maintained by Ascendiant Capital -- Price Target Raised to $10.25 - GuruFocus
Allarity Therapeutics (ALLR) Slides 5.3% as Stock Tests Critical Support LevelGap Fill Strategy - newsline.com
Are medical stocks lagging Allarity Therapeutics, Inc. (ALLR) this year? - MSN
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year? - Yahoo Finance
Amended and Restated Management Services Agreement Between Allarity Therapeutics, Inc. and Ljungaskog Consulting AB Effective June 1, 2026 - Minichart
Allarity Therapeutics Updates CEO Management and Compensation Agreement - TipRanks
Allarity (NASDAQ: ALLR) updates CEO pay and severance terms - Stock Titan
Number of shareholders of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
ALLR Q1 2026 Earnings: Narrower Loss Surprises as Pre-Revenue Biotech Advances PipelineGuidance Downgrade Alert - The Legal Advocate
Allarity Therapeutics (ALLR) Faces Selling Pressure, Holds Above Key SupportVolatility Smile - thelegaladvocate.com
Allarity Therapeutics (ALLR) Slides 4.8% in Session; Key Support Levels in FocusGEX Level - newsline.com
Allarity Therapeutics (ALLR) Surges 6.6% as Volume Picks Up, Testing Key ResistanceOption Breadth - The Legal Advocate
Allarity (ALLR) Posts Q1 2026 Earnings Beat — Here's What Drove ItPre-Announcement Alert - The Legal Advocate
Allarity (ALLR) Delivers Q1 2026 Beat — EPS $-0.17 vs $-0.22 ExpectedEarnings Season Preview - The Legal Advocate
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
Allarity Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Allarity Therapeutics Advances Stenoparib Development for Cancer Treatments and Strengthens Financial Position - Quiver Quantitative
Allarity Therapeutics Q1 net loss per share narrows - TradingView
U.S. VA backs trial of Allarity cancer drug for relapsed lung patients - Stock Titan
Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Allarity Therapeutics (ALLR) posts Q1 2026 loss but lifts cash with $20M notes - Stock Titan
Allarity Therapeutics (ALLR) CEO receives 200,000-share RSU equity grant - Stock Titan
Why Allarity (ALLR) Just Dropped -1.30% — What to Watch 2026-05-14Trade Entry - newser.com
Director Jesper Hoeiland receives 25,000-share grant at Allarity (ALLR) - Stock Titan
Director Jesper Hoeiland joins Allarity Therapeutics (ALLR) with initial Form 3 filing - Stock Titan
Allarity Therapeutics Advances Stenoparib, a Dual PARP and WNT Inhibitor with DRP® Companion Diagnostic, in Phase 2 Cancer Trials - Minichart
Allarity Highlights Stenoparib Progress in New Investor Presentation - TipRanks
Allarity details stenoparib data, CEO to speak in Europe | ALLR 8-K Filing - Stock Titan
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm - The Manila Times
Allarity Therapeutics CEO Thomas Jensen to Speak at Precision Medicine Forum Europe 2026 - Quiver Quantitative
Allarity CEO to outline cancer drug trial work at Stockholm forum - Stock Titan
Director at Allarity Therapeutics (ALLR) receives 45,000 RSUs in grant - Stock Titan
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - TMX Newsfile
Allarity Therapeutics Advances Stenoparib Toward Phase 3 and FDA Approval in Ovarian Cancer with Manufacturing Milestone - Minichart
Stenoparib Phase 3 manufacturing on track as Allarity (NASDAQ: ALLR) preps trials - Stock Titan
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign - Investing News Network
Allarity advances stenoparib manufacturing for pivotal trial By Investing.com - Investing.com South Africa
Allarity advances stenoparib manufacturing for pivotal trial - Investing.com India
Allarity readies ovarian cancer drug with no more manufacturing cash due - Stock Titan
What Allarity (ALLR) is doing to earn customer loyalty (Institutional Demand) 2026-05-05Inverse ETF Flow - newsline.com
[ARS] Allarity Therapeutics, Inc. SEC Filing - Stock Titan
Allarity Therapeutics (NASDAQ: ALLR) details 2026 votes on ELOC, pay and equity plan - Stock Titan
Equity grant gives Allarity Therapeutics (ALLR) officer 133,333 RSUs - Stock Titan
Allarity Therapeutics (ALLR) CFO awarded 150,000 restricted stock units - Stock Titan
USPTO allows Allarity (NASDAQ: ALLR) stenoparib DRP patent with exclusivity to 2039 - Stock Titan
Allarity receives USPTO patent notice for stenoparib diagnostic - Investing.com UK
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office - Investing News Network
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):